OpenLobby.EU
Explore

Chiesi Farmaceutici SpA

Chiesi

Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care.

Lobbying Activity

Meeting with Vytenis Povilas Andriukaitis (Member of the European Parliament)

3 Jun 2025 · Introductory meeting

Response to EU Life sciences strategy

17 Apr 2025

The Chiesi Group welcomes the opportunity to contribute to the call for evidence on the upcoming EU Life Sciences strategy. We are a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The companys mission is to improve peoples quality of life and act responsibly towards both the community and the environment. The groups recent investments in a Biotech centre and a new manufacturing site in Italy underscore Chiesis commitment to bioinnovation, reflecting one of the key pillars highlighted by Mario Draghi in his report on EU competitiveness to address the challenges faced by European industry. The life sciences sector plays a crucial role not only in driving economic growth and creating jobs but also in addressing unmet medical needs and enhancing the health of the EU population. In order to support biopharmaceutical companies investing in Europe, the European Union (EU) should develop an ambitious Life Sciences strategy to revive its Life Sciences ecosystem. The EU scientific community enjoys the advantages of a strong education system and lower costs compared to non-EU biotechnology hubs. However, the fragmented market of the 27 EU Member States and the lack of harmonized commercial opportunities hinder the conversion of this excellence into innovative and profitable projects, making other regions more attractive. Public authorities outside the EU often have more consistent priorities and funding mechanisms, whereas the EU's approach is more dispersed and varies according to national priorities and healthcare systems. Indeed, several EU countries are developing their own national health strategies that should be brought into a coherent EU framework. Therefore, a thriving interconnected ecosystem is essential, covering everything from basic research and clinical development to commercial viability across EU countries. Chiesi believes resources should be pooled together to exploit synergies across the different life sciences hubs and innovative clusters to reach critical mass, to reduce fragmentation and to exploit complementarities able to attract, train and retain top-tier life sciences specialists, entrepreneurs and capitals. Supporting and developing synergistic innovative regional clusters across the EU will create dynamic ecosystems where scientific results may be exploited nurturing pan European projects and enabling specialists to collaborate and exchange expertise. This approach will amplify the effectiveness of these strategies and accelerate progress within the life sciences sector. A successful life science strategy can only be the outcome of several legislative and non legislative elements coming together in different areas: streamlining funding into a limited number of clearly defined priorities; enabling the use of key technologies such as Artificial Intelligence (AI); ensuring better implementation of European initiatives and legislation within the Member States in order to avoid excessive fragmentation during their practical application (HTA, clinical trials, etc.); proper implementation of the European Health Data Space; a regulatory environment fit for purpose; the availability of relevant academic curricula and skills; a closer private and public cooperation in R&D; a stronger EU capital market; adequate investments in national healthcare systems; the presence of a competitive market that attracts, correctly values and rewards innovation in line with other economies at the forefront of patient care.
Read full response

Meeting with Carlo Fidanza (Member of the European Parliament)

8 Apr 2025 · Introductory meeting

Meeting with Aurelijus Veryga (Member of the European Parliament)

8 Apr 2025 · How responsible pharma can create value for patients, society, and the environment

Meeting with Aldo Patriciello (Member of the European Parliament)

20 Mar 2025 · Rare diseases policies

Response to EU Start-up and Scale-up Strategy

17 Mar 2025

The Chiesi Group welcomes the opportunity to contribute to the public consultation on the EU Startup and Scaleup Strategy. We are a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The companys mission is to improve peoples quality of life and act responsibly towards both the community and the environment. The Chiesi Groups research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden, offering us a perspective on the dynamic ecosystem of startups. Health-related startups in the EU can face various sector specific challenges, including navigating the 27 distinct healthcare systems and differing national rules potentially raising costs for start-ups in the EU relative to other regions. In addition, Europe would see strong benefits in creating a single capital market, especially for early-stage investments (pre-Series A), along with alleviating bureaucratic complexities that may slow cross-border expansion. Therefore, in order to build a globally competitive European startup ecosystem, a systemic and coordinated approach is required: this can be done via the development of the aforementioned integrated European capital market to boost institutional investment in venture capital or expanding R&D financing frameworks to better support startup-driven innovation (e.g., an EU SBIR/STTR program (reinforcing the actual EIC approach)). At the same time, health-related startups can also face barriers in commercializing science and innovation in Europe. EU universities often lack structured long-term collaboration frameworks with industry, whereas industrial silos prevent startups from leveraging innovations across multiple sectors. Accordingly, ensuring consistent accessibility to national infrastructure investments, including NextGenEU funds, for startups would be a strong step in the right direction. To this end, regulatory & market harmonization initiatives should be prioritized, simplifying cross-border compliance for scaling startups. Universities should be incentivized to actively engage in structured partnerships with industry and there should be further support offered to public-private R&D collaborations across EU borders. Simultaneously, startups in Europe encounter limited access to finance versus other regions, especially the US, along with talent retention and challenges in scaling sustainable innovation. European startups receive significantly less funding than US counterparts, particularly but not only, in later-stage growth capital. In order to support European startups, public procurement & scale-up support would simplify access to government contracts for startups (e.g., a G-Cloud model). This could be achieved via the creation of targeted support programs for scale-ups beyond the early funding stage. Last, sustainability should be seen as a competitive advantage, supporting deep-tech and cleantech startups with long-term sustainability funding models. This would include ensuring that sustainability regulations for startups are growth-enabling, providing clarity and allowing start-ups to embrace the green transition. The EU must move beyond fragmented initiatives to establish a coherent, holistic framework for startup and scale-up growth. Financial resources alone are not enoughwe need a fundamental cultural and structural shift. A unified, pan-European approach that integrates investment, regulation, talent, and commercialization pathways will position EU startups as global leaders in innovation and sustainability.
Read full response

Meeting with Valentina Palmisano (Member of the European Parliament)

6 Feb 2025 · Incontro conoscitivo

Meeting with Michele Picaro (Member of the European Parliament)

15 Jan 2025 · Pharmaceuticals

Meeting with Giorgio Gori (Member of the European Parliament)

13 Nov 2024 · Presentation of priorities

Meeting with Letizia Moratti (Member of the European Parliament)

13 Nov 2024 · Health Policies

Meeting with Elisabetta Gualmini (Member of the European Parliament)

13 Nov 2024 · ITRE Committee

Meeting with Stefano Cavedagna (Member of the European Parliament)

24 Sept 2024 · Introductory meeting

Meeting with Bas Eickhout (Member of the European Parliament) and Google and

29 Nov 2022 · Politico's Sustainable Future Week 2022

Meeting with Jutta Paulus (Member of the European Parliament, Shadow rapporteur) and Siemens Energy AG

6 Sept 2022 · F-Gas Regulation

Response to Review of EU rules on fluorinated greenhouse gases

29 Jun 2022

Please find attached Chiesi's comments.
Read full response

Meeting with Salvatore De Meo (Member of the European Parliament)

20 Jun 2022 · Various

Meeting with Salvatore De Meo (Member of the European Parliament) and Stellantis and Alibaba

13 Oct 2021 · Various

Meeting with Daniel Calleja Crespo (Director-General Environment)

30 Apr 2020 · Environment sustainability

Meeting with Giulia Del Brenna (Cabinet of Commissioner Carlos Moedas)

24 Feb 2016 · Presentation of Chiesi's innovation pipeline